Action 300685 AMOY DIAGNOSTICS CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Amoy Diagnostics Co., Ltd.

Actions

300685

CNE1000034D3

Cours en clôture Shenzhen S.E.
Autres places de cotation
 00:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
21,55 CNY +2,13 % Graphique intraday de Amoy Diagnostics Co., Ltd. -1,06 % -1,96 %
22/04 Amoy Diagnostics Co. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
15/04 Amoy Diagnostics Co. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
Amoy Diagnostics Co., Ltd.'s Equity Buyback announced on February 13, 2023 has expired with 3,943,726 shares, representing 1% for CNY 112.01 million.
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 300685
  4. Actualités Amoy Diagnostics Co., Ltd.
  5. Autres langues